Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 2, 2009, Pages 155-159

  Lerner, Seth P ^a   Tangen, Catherine M ^b   Sucharew, Heidi ^b   Wood, David ^c   Crawford, E David ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Statistical Center   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

BCG; Bladder cancer; Immunotherapy; Intravesical therapy; Maintenance; Non muscle invasive

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE;

ADULT; ARTICLE; BLADDER CARCINOMA; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE EXACERBATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; BCG VACCINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RISK; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 61649110957     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.11.033     Document Type: Article

References (20)

1. Kelley D.R., Ratliff T.L., Catalona W.J., et al. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: Effect of bacillus Calmette-Guerin viability on treatment results. J Urol 134 1 (1985) 48-53
2. Herr H., Schwalb D.M., Zhang Z.F., et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: 10-year follow-up of a prospective randomized trial. J Clin Oncol 13 6 (1995) 1404-1408
3. Cookson M.S., and Sarosdy M.F. Management of Stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol 148 3 (1992) 797-801
4. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1A, and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol 163 4 (2000) 1124-1129
5. Esuvaranathan K., Kamaraj R., Mohan R.S., et al. A Phase IIB trial of BCG combined with interferon alpha for bladder cancer. J Urol 163 Supp (2000) [Abstract]
6. Joudi F.N., Smith B.J., and O'Donnell M.A. Final results from a national multicenter Phase II trial of combination bacillus Calmette-Guerin plus interferon α-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24 4 (2006) 344-348
7. Griffiths T.R., Charlton M., Neal D.E., et al. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 167 6 (2002) 2408-2412
8. Kurth K.H., Denis L., Bouffioux C., et al. Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer 31A 11 (1995) 1840-1846
9. Dinney C.P., Babkowski R.C., Antelo M., et al. Relationship among cystectomy, microvessel density, and prognosis in Stage T1 transitional cell carcinoma of the bladder. J Urol 160 4 (1998) 1285-1290
10. Gupta A., Lotan Y., Nielsen M., et al. Outcomes of patients with clinical T1 Grade 3 bladder urothelial carcinoma treated with radical cystectomy. J Urol 177 (2007) 498 [Abstract 1511]
11. LeBlanc M., Crowley J., et al. Relative risk regression trees for censored survival data. Biometrics 48 (1992) 411-425
12. Solsona E., Iborra I., Dumont R., et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164 3 Pt 1 (2000) 685-689
13. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19 3 (2001) 666-675
14. Dutta S.C., Smith Jr. J.A., Shappell S.B., et al. Clinical under staging of high risk non-muscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166 2 (2001) 49-3
15. Herr H.W., Donat S.M., and Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?. J Urol 177 1 (2007) 75-79 Discussion 79
16. Jurincic-Winkler C.D., Metz K.A., Beuth J., et al. Keyhole limpet hemocyanin for carcinoma in situ of the bladder: A long-term follow-up study. Eur Urol 37 Suppl 3 (2000) 45-49
17. O'Donnell M.A., Krohn J., and De Wolf W. Salvage intravesical therapy with interferon-α2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 166 4 (2001) 1300-1305
18. Dalbagni G., Russo P., Sheinfeld J., et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20 15 (2002) 3193-3198
19. Steinberg G., Bahnson R., Brosman S., et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 163 3 (2000) 761-767
20. Takashi M., Wakai K., Hattori T., et al. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: Significance of concomitant carcinoma in situ. Int Urol Nephrol 33 1 (2002) 41-47